Role of drug and therapeutics committee towards drug safety-experiences from western Nepal

Kathmandu University Medical Journal

Volumn 3 no. 1, Issue 9, 2005, Pages 79-80

  Palaian, S ^a   Mishra, P ^a  

^a MANIPAL COLLEGE OF MEDICAL SCIENCES   (Nepal)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG THERAPY; HUMAN; NEPAL; PHARMACY AND THERAPEUTICS COMMITTEE; SAFETY;

DRUG THERAPY; HUMANS; NEPAL; PHARMACY AND THERAPEUTICS COMMITTEE; SAFETY MANAGEMENT;

EID: 33748665340     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. th ed. Philadelphia: Lea and Feibiger, 1986: 91-123.
2. Anon: FDA Talk Paper: FDA issues public health warning on phenylpropanolamine; United States Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD, November 6, 2000. Available at: http://www.fda.gov/bbs/ topics/ANSWERS/ANS01051.html (cited 11/2000)
3. Anon: SCRIP World Pharmaceutical News. PJB Publications, Ltd., London; No 2732, March 27, 2002, p 19
4. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49:2229-32.
5. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-245